Search clinical trials for: PF-06865571

Total 1296 results

Pfizer

Completed

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Grupo Espanol de trasplantes hematopoyeticos y...

Active, not recruiting

Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease

Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder)

Spain
Pfizer

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Yale University

Completed

Cannabinoid Augmentation of Fear Response in Humans

Fear Conditioning

United States
Pfizer

Terminated

Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants

Healthy

Belgium
Biogen

Completed

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia (MAD)

Schizophrenia

United States
Pfizer

Completed

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

Hypertension

United States
Grupo Español de Investigación en Neurooncología
Pfizer

Completed

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Glioblastoma | Brain Tumor, Recurrent

Spain
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Pfizer

Completed

Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis (HER-Uro01)

Carcinoma, Squamous Cell | Penile Neoplasms

Italy
Biogen

Completed

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

Healthy

United States
Pfizer

Completed

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Carcinoma, Non-small Cell

United States, Taiwan, Korea, Republic of, Japan, Hong Kong
Pfizer

Completed

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

Healthy

United States
Pfizer

Completed

A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults

Healthy

Japan
Pfizer

Completed

PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Study for MR Formulation of PF-06650833 in Healthy Adult Japanese Subjects

Healthy

Japan
Pfizer

Completed

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

Normal Healthy

United States
Pfizer

Completed

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512

Healthy

Belgium
Pfizer

Terminated

Safety and Tolerability of PF-06818883 in Healthy Subjects

Healthy

United States
Pfizer

Completed

First in Human Study for PF-06667272

Healthy

Belgium
Pfizer

Terminated

A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Unknown

Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer

Skin Squamous Cell Cancer

Italy
Pfizer

Completed

Single Dose Study of PF-05230907 in Healthy Japanese Subjects

Healthy

United States
Pfizer

Completed

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

Diabetic Nephropathy

United States, Spain, Korea, Republic of, Australia, Hong Kong, Germany, Poland, Italy, Canada, Puerto Rico, Malaysia, Romania, Argentina, Peru
Pfizer

Completed

A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects

Healthy Subjects

Belgium
Pfizer

Completed

A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects

Healthy

United States
Pfizer

Completed

Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

Safety And Tolerability Study Of BID Titration Scheme With PF-05089771

Healthy

United States
Pfizer

Completed

Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects

Healthy

United States
Pfizer

Completed

A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162

Healthy

United States
Pfizer
Medivation, Inc.

Terminated

An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

Alzheimer's Disease

Canada, United States, Puerto Rico
Pfizer

Completed

Multiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects

Respiratory Tract Infections

United States
Taisho Pharmaceutical Co., Ltd.

Completed

Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers

Healthy

Singapore
Taisho Pharmaceutical Co., Ltd.

Completed

Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Terminated

A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers

Healthy | Elderly

United States
Pfizer

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B (BENEGENE-2)

Hemophilia B

Germany, United Kingdom, Canada, Australia, Taiwan, Japan, France, Turkey, Korea, Republic of, United States, Brazil, Greece, Saudi Arabia, Sweden
Pfizer

Active, not recruiting

Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

Muscular Dystrophy, Duchenne

United States, Australia
Pfizer

Completed

Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants

Healthy

Japan
Cerevel Therapeutics, LLC

Completed

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Schizophrenia

Belgium, United States
Biogen

Completed

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY)

Cognitive Impairment Associated With Schizophrenia

Spain, United States, Germany, Japan, United Kingdom
University of Colorado, Denver
The Leukemia and Lymphoma Society

Completed

PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission

United States
Pfizer

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

Hepatic Impairment | Healthy Participants

United States
Pfizer

Completed

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Severe Hepatic Impairment

United States
Pfizer

Completed

Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers

Healthy | Sleep

United States
Pfizer

Completed

A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

Colitis, Ulcerative

Canada, United States, France, Netherlands, Germany, Spain, Austria, Hungary, Bulgaria, Poland, Romania
Pfizer

Completed

6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria

Diabetic Nephropathy

Canada
Foundation for Innovative New Diagnostics, Switzerland

Unknown

Performance Evaluation of Malaria Plus RDTs

Malaria

3

Subscribe